UK company record
Enara Bio
Immuno-oncology (TCR-based therapeutics, 'Dark Antigens')
CandidateCore UK
Snapshot
- UK location
- Oxford · South East
- Sector
- Biotech & techbio
- Latest recorded round
- Series B
- Latest recorded amount
- $32.5M
- Date
- 2024-10-01
Legal-identity layer
Candidate identity.
- Selected legal name
- ENARA BIO LIMITED
- Company number
- 10469748
- Companies House status
- active
- Incorporated
- 2016-11-08
Investors
- M VenturesLead
- Pfizer VenturesLead
- RA CapitalParticipant
- Samsara BioCapitalParticipant
- SV Health InvestorsParticipant
- The Francis Crick InstituteParticipant
Current directors and active controllers
- AL-HALLAQ, Rana Abdul Raouf, DrCurrent director
- ANG, Robert Yuen Lee, DrCurrent director
- ANNINGA, Bauke, DrCurrent director
- BINGHAM, Catherine Elizabeth, DameCurrent director
- DYBBS, Michael PhilipCurrent director
- POJASEK, Kevin RobertCurrent director
- RESNICK, Joshua BenjaminCurrent director
- WOOD, Clive RossCurrent director
- ASHRAFIAN, Houman, Professordirector
- BINGHAM, Catherine Elizabethdirector
- DINES, Jonathon Alandirector
- EDWARDS, Timothy Peter Warrendirector
- Peter KolchinskyFormer controller
- Professor Houman AshrafianFormer controller
- Rajeev ShahFormer controller
Funding rows
- Series B$32.5M · 2024-10-01
Sources
- https://enarabio.com/news/enara-bio-raises-32-5-million-series-b-financing-to-advance-first-in-class-pipeline-of-tcr-based-immunotherapies-targeting-novel-dark-antigens
- https://www.m-ventures.com/news/enara-bio-raises-32-5-million-series-b-financing-to-advance-first-in-class-pipeline-of-tcr-based-immunotherapies-targeting-novel
- https://www.m-ventures.com/news/enara-bio-raises-32-5-million-series-b-financing-to-advance-first-in-class-pipeline-of-tcr-based-immunotherapies-targeting-novel